Hard to Treat Diseases, Incorporated Receives Court's Order Regarding Summary Judgment
Thursday January 27, 3:25 pm ET
DELRAY BEACH, Fla., Jan. 27, 2005 (PRIMEZONE) -- Hard to Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) received the Court's Order today Denying Plaintiff's Motion For Summary Judgment & Denying Defendant's Cross Motion For Summary Judgment. A copy of the Court's Order signed January 25, 2005 can be viewed on our website at: htdsotc.com
It is the Company's understanding that Summary Judgment requires a finding that there are no material issues of genuine fact. Both Defendants, Shinn and Knight, have contested whether the Share Exchange Agreement closed and whether HTTD is entitled to the rights of Tubercin(R).
The Court found that there are factual issues that must be determined in a setting other than a Motion for Summary Judgment because a Summary Judgment is only appropriate for the resolution of issues in which the material issues of genuine fact are undisputed. The Court denied both the Plaintiff's and Defendant's motions.
It is the Company's position that both Shinn and Knight have admitted that they were officers and directors of HTTD because of their statements in court documents, their press releases, their signed Board Minutes, their signed Corporate Resolutions, their representations to the world and numerous correspondence.
It is also the Company's position that both Shinn and Knight have admitted to the consummation, acceptance and closing of the Share Exchange Agreement through their press releases, their signed Board Minutes, their signed Corporate Resolutions, their correspondence, their representations to the world and their signed correspondence to Dr. Chung, the inventor and patent-holder of Tubercin(R).
We are fully confident in the judiciary and the legal process under which HTTD is proceeding.
Management's intention and goal with this litigation is to resolve the current dispute in the most efficient and economical manner to provide the maximum benefit to the Company and to HTTD's shareholders.
HTTD is currently involved in litigation regarding the rights to Tubercin(R). Additional information and details regarding the litigation can be viewed at our website at: htdsotc.com
_________________
If what you did yesterday isn't working, change it!!!! |
